Kiniksa Pharmaceuticals Ltd - Class A is a biopharmaceutical company focusing on the discovery, development, and commercialisation of therapeutic medicines. Operating globally, it addresses several debilitating diseases with significant unmet medical need.
Operating in the healthcare sector, Kiniksa Pharmaceuticals has a pipeline of clinical-stage, immune-modulating product candidates that target conditions such as recurrent pericarditis and rheumatoid arthritis. Included in its portfolio is the development of treatments and therapies for autoinflammatory, cardiovascular and autoimmune diseases.
Stay up to date on the share price of KNSA by adding it to your eToro watchlist.